| 刘燕汝,刘 丽,孙 青,李 娜,周晓丹.帕拉米韦氯化钠注射液对流感病毒A型肺炎患儿的成本-效益分析[J].现代生物医学进展英文版,2021,(4):678-682. |
| 帕拉米韦氯化钠注射液对流感病毒A型肺炎患儿的成本-效益分析 |
| The Cost-benefit Analysis of Peramivir Sodium Chloride Injection in Children with Influenza Virus Type A Pneumonia |
| Received:May 06, 2020 Revised:May 30, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.04.016 |
| 中文关键词: 帕拉米韦氯化钠注射液 磷酸奥司他韦 流感病毒A型肺炎 成本-效益 不良反应 |
| 英文关键词: Peramivir sodium chloride injection Oseltamivir phosphate Influenza virus A pneumonia Cost-effectiveness Adverse reactions |
| 基金项目:国家卫生计生委资助项目（CHEA1314060604） |
|
| Hits: 991 |
| Download times: 544 |
| 中文摘要: |
| 摘要 目的：探讨帕拉米韦氯化钠注射液对流感病毒A型肺炎患儿的成本-效益。方法：选择我院2015年1 月至2018年12月收治的96例流感病毒A型肺炎患儿，根据随机数字表法，将96例患儿分为A组及B组，每组48例，A组患儿给予磷酸奥司他韦颗粒，B组患儿给予帕拉米韦氯化钠注射液，对比两组患儿的治疗效果、临床症状消失时间、住院时间、用药成本、成本-效益，对比两组患儿治疗前及治疗后的血常规及肝肾功能，对比两组患儿的不良反应发生率。结果：B组患儿的治疗有效率明显较A组高（P<0.05）。观察组患儿的临床症状消失时间及住院时间明显较对照组低（P<0.05）。A组患儿的平均用药成本明显低于B组（P<0.05），A组的成本-效益较B组低。与治疗前相比，治疗后两组患儿的中性粒细胞总数明显升高，白细胞总数、淋巴细胞总数明显降低（P<0.05）；而治疗前后，两组患儿的血常规指标对比无统计学意义（P>0.05）。治疗前后，两组患儿的肝肾功能对比均无统计学意义（P>0.05）。B组患儿的不良反应发生率较A组高，但组间对比无统计学意义（P>0.05）。结论：与磷酸奥司他韦相比，帕拉米韦氯化钠注射液对流感病毒A型肺炎患儿的疗效更佳，但其成本-效益较低，临床上可根据患儿实际情况选择用药。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the cost-benefit analysis of peramivir sodium chloride injection in children with influenza virus type A pneumonia. Methods: 96 children with influenza virus A pneumonia admitted to our hospital from January 2015 to December 2018 were selected, who were divided into two groups according to the random number table method, each group had 48 cases, group A were given Oseltamivir phosphate granules, group B were given Peramivir sodium chloride injection, the treatment effect, clinical symptoms disappearance time, stay length , medication cost, cost-benefit in two groups were compared, the blood routine and liver and kidney function before and after treatment were compared in two groups, and the incidence of adverse reactions was compared between the two groups. Results: The effective rate of treatment in group B was significantly higher than that in group A (P<0.05). The average drug cost of group A was significantly lower than that of group B(P<0.05), and the cost-benefit of group A was lower than that of group B(P<0.05). Compared with before treatment, the total number of neutrophils was significantly increased, and the total number of white blood cells and lymphocytes were significantly decreased in two groups after treatment(P<0.05). Before and after treatment, there were no statistical significance in blood routine indexes of two groups (P>0.05). Before and after treatment, there was no statistical significance in liver and kidney function of two groups(P>0.05). The incidence of adverse reactions in group B was higher than that in group A, but the comparison between groups was not statistically significant(P>0.05). Conclusion: Compared with Oseltamivir phosphate, Peramivir sodium chloride injection has better efficacy in the treatment of children with influenza virus type A pneumonia, while the cost-benefit was low, and medication could be selected according to the actual situation of children. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
